Earli
Phil Greenberg leads the Program in Immunology at the Fred Hutchinson Cancer Research Center in Seattle. He has been instrumental in the discovery of the principles of T-cell and tumor interactions and translating key insights to cancer therapies with genetically engineered T cells. Phil is also the scientific co-founder of Juno Therapeutics, which was acquired for $9B by Celgene in 2018. He served as an elected member of the Board of Directors of the American Association for Cancer Research, and currently is an Editor-In-Chief of the journal Cancer Immunology Research. As frequently as possible, Phil escapes to the slopes in Whistler or Crystal Mountain for skiing.
This person is not in the org chart
This person is not in any offices
Earli
1 followers
Earli has an ambitious mission: to force cancer reveal its location at its earliest stages, which makes it quickly treatable. In other words, they aim to make cancer a benign experience. Their science is based on a new method of detecting, localizing and then treating cancer called "Synthetic Biopsies," originally developed by the late Dr. Sam Gambhir at Stanford.